A key reason for that amongst others is the lack of an appropriate biotech financing environment. Despite the lack of sufficient innovation capital, a few selected EU companies have managed to close financially attractive deals with US pharmas. This shows that there is a good technological basis but a lack of drug development efforts in the EU. One company that has demonstrated remarkable profitability just by dealmaking is Phenex Pharmaceuticals by generating revenues in the 100s of millions just with 25 employees. This talk will briefly summarize the key success factors of Phenex’s approach so far and will outline a strategic perspective how to build a biotech company in Europe from scratch to market success.
Pricing pressure will be a driving factor for the industry to move from a pure fee-for-service model to value-based care. Advances in diagnostics and personalized medicine will change our conventional business model. Increasingly non-traditional players will enter the health care marketplace.
What are the questions we need to ask today, to have the right answers for tomorrow’s biopharmaceutical world? This presentation will give you an overview of some of the challenges the industry will face by 2020 and which role market research can play.
• Healthcare cost drivers and cost-containment strategies
• The era of empowered patients: a shift in power within healthcare
• New players that are entering and reshaping the healthcare landscape
• Technologies and innovation impacting the future of healthcare
As patients become increasingly involved in their own health and healthcare systems demand more evidence of outcomes, pharmaceutical organisations have been moving towards a business model that puts patients at the heart of everything they do. In this paper we will deliberate the meaning of patient centricity and why it is so important, the impact of patient centricity on pharma/biotech, discuss relevant case studies on supporting patient centricity through research and finally considerations for the future for patient centricity.
• This talk discusses how to build “best practices” for your team, integrating relevant and complimentary functional roles and findings from MR and CI.
• By integrating key learnings from both practices, companies are able to harness strategic and actionable insight into the biopharmaceutical sector.
Unfortunately, predictive analytics used to support commercialization and manage uncertainty must often rely on scanty data from small survey samples that push the boundaries of statistical confidence. We all know the routine cautions but we don’t necessarily know the permissions – and what risks are worth taking. This talk shares empirical findings that systemically map the small data space to determine where models built on samples smaller than 50 are most vulnerable, and what tactics that can be used to shore them up. Researchers can expect practical guidance on how to minimize risk, with important applications for early-stage commercial strategy and models built on small specialties or regional populations.
But the real world isn’t necessarily linear. Patients and care providers act within a complex ecosystem of interacting forces that shape the choices they make. This talk follows a patient’s journey through the Sickle Cell Ecosystem, exposing the often hidden influence of stakeholders such as employers and community groups over decisions made in the clinic.
Since the introduction of the first biosimilar Omnitrope in 2006, 27 more biosimilars have been launched in Europe challenging the original brands at lower cost in various diseases. Especially the recent breakthrough entry of biosimilar monoclonal antibodies have brought a new level of complexity, making it a much tougher environment for biologics originators. It’s no longer just about lowering costs.
In this presentation we share our views on how market research and analytics can help forecast and impact the uptake of biosimilars in different market situations. We put these views into practice by sharing learnings and challenges from a recent uptake study in the area of rheumatology among physicians and pharmacists.
Do you want to engage more effectively with your key stakeholders to promote a richer response?
Do you want to excite your brand teams with innovative techniques to enhance brand communications?
Do you want to explore the value and benefit of using gamification to drive response rates and better insights?
1. How the application of innovative methods can make research more interactive and engaging, resulting in more insightful outcomes
2. How to generate emotional insights using games and how to use these to enhance brand communications
This talk will share the practical value of gamification and interactive research techniques. Be prepared to become a change agent in our industry.
• Research approaches addressing pricing questions.
• Tool variation based on the product, its place in the product lifecycle and market requirements.
• Key pricing techniques and the best approaches for differing product needs.
• Showing both qualitative and quantitative approaches in pricing optimization.